Q2 2026 Merit Medical Systems Inc Earnings Call Transcript
Key Points
- Merit Medical Systems Inc (MMSI) delivered its strongest quarterly organic growth in three years, with total revenue of $418.8 million, up 9% on a constant currency basis, exceeding the high end of expectations.
- The company reported significant profitability improvements, with non-GAAP operating margin increasing 142 basis points year-over-year to 22.6% and non-GAAP EPS rising 18% year-over-year.
- Acquisitions are performing well, with Biolife and C2 CryoBalloon both exceeding revenue expectations, leading to increased annualized revenue projections of approximately $23 million and $8-9 million, respectively.
- The company successfully launched the OneMark system and Scout MD technology, expanding its oncology portfolio and providing a comprehensive breast care offering that is resonating well with clinicians.
- Merit Medical Systems Inc (MMSI) raised its full-year 2026 guidance for revenue and non-GAAP EPS, reflecting strong first-half performance and confidence in continued execution.
- The company generated nearly $52 million in free cash flow during Q2 and maintains a strong balance sheet with a net leverage ratio of 1.6 times, supporting future strategic investments.
- The company faces ongoing headwinds from tariffs, with a projected $16 million or $0.21 per share impact on 2026 earnings, and the dynamic tariff environment creates uncertainty for future guidance.
- Sales of Greenall Therapies products declined 2% due to the lingering impact of a product recall, and while resolved, it will take time to recapture lost accounts and revenue.
- The OEM business, while showing strong 15% growth in Q2, is inherently lumpy, and the company expects it to normalize to mid-to-high single-digit growth annually, which may not be sustainable.
- Q3 guidance indicates a sequential step-down in organic growth to 7-8% from Q2's 9%, reflecting typical seasonality but also suggesting a moderation in the recent growth pace.
- The company's strategic planning process for 2027-2029 is ongoing, creating some uncertainty about future portfolio composition, potential divestitures, and long-term financial targets.
- Inventory levels increased by over $20 million in the quarter due to strategic stocking decisions, which could tie up cash and impact future working capital efficiency.
Welcome to Merit Medical Systems second quarter 2026 earnings conference call. (Operator Instructions) Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Martha Aronson, Merit Medical Systems President and Chief Executive Officer.
Thank you, operator, and welcome, everyone. I am joined on the call today by Raul Parra, our Chief Financial Officer and Treasurer, and Brian Lloyd, our Chief Legal Officer and Corporate Secretary. Brian, would you mind taking us through the safe harbor statements, please?
Thanks, Martha. This presentation contains forward-looking statements that receive safe harbor protection under federal securities laws. Although we believe these forward-looking statements are based upon
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
